⭐ Start off 2025 with a powerful boost to your portfolio: January’s freshest AI-picked stocksUnlock stocks

Raymond James lifts MAXIMUS stock rating to Outperform

EditorAhmed Abdulazez Abdulkadir
Published 01/02/2025, 05:33 AM
MMS
-

On Thursday, Raymond (NS:RYMD) James analyst upgraded shares of MAXIMUS, Inc. (NYSE: MMS) from Market Perform to Outperform, setting a price target of $90.00. Gesuale cited a compelling valuation for the upgrade, noting that the company's multiple has compressed from 10.5x to 9.3x since the recent election.

Currently trading at a P/E of 14.82x, InvestingPro analysis indicates the stock is undervalued, with a perfect Piotroski Score of 9 reflecting strong financial fundamentals. He highlighted that the stock is currently trading at a discount compared to its historical relationship with its peer group.

The analyst pointed out that MAXIMUS shares have declined by 12% year-to-date, underperforming relative to the group and market gains of 17% and 27%, respectively. According to Raymond James, this presents an attractive valuation opportunity. With a strong current ratio of 1.49 and 20 consecutive years of dividend payments, InvestingPro data shows MAXIMUS maintains solid financial health, earning a "GOOD" overall rating. He believes that MAXIMUS has cleared several major hurdles, including the CCO contract, the OUS divestiture, and the VA contract recompete.

The analyst emphasized that with these challenges now in the past, MAXIMUS is positioned with a battered stock price, fewer distractions, and a revenue mix that is more resilient than many may assume. With revenue growth of 8.19% in the last twelve months and moderate debt levels, the company shows promising fundamentals. Gesuale also identified multiple potential growth catalysts for the company, such as the upcoming Census 2030, the IRS EDOS, and TSA projects.

The upgrade reflects a positive outlook for MAXIMUS, as the company appears to be moving beyond previous operational obstacles. With the reduced stock price and potential for growth, Raymond James sees the current situation as an opportune moment for investors. The new price target of $90.00 represents a significant increase from the current trading levels, suggesting confidence in the company's future performance.

In other recent news, Maximus (NYSE:MMS) has seen a series of significant developments. The company reported a robust fiscal year 2024 performance, with an organic revenue increase of 8.8% and a record adjusted earnings per share (EPS) of $6.11. Free cash flow also saw a substantial rise, reaching over $400 million, almost double the previous year's figure.

Additionally, Maximus announced an increase in its stock repurchase program by $200 million, following the completion of the previous $200 million stock buyback authorization. The company also made a notable change in its auditing responsibilities, dismissing Ernst & Young LLP and appointing KPMG LLP for the fiscal year ending September 30, 2025.

However, the company's contract with the U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services for Contact Center Operations was cancelled recently. Despite these developments, Maximus is projecting fiscal 2025 revenue to be between $5.275 billion and $5.425 billion, with an adjusted EPS forecasted to be in the range of $5.70 to $6.00 per share. These recent developments are essential for investors to consider as Maximus navigates its future financial trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.